Boothbay Fund Management’s CRISPR Therapeutics CRSP Stock Holding History

Boothbay Fund Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-159,500	Closed	-$9.98M	–	1630
2023 Q4	$9.98M	Buy	159,500 +114,800	+257%	+$6.35M	0.25%	63
2023 Q3	$2.03M	Buy	44,700 +3,900	+10%	+$201K	0.05%	490
2023 Q2	$2.29M	Buy	+40,800	New	+$2.32M	0.05%	507
2021 Q4	–	Sell	-19,900	Closed	-$2.23M	–	1911
2021 Q3	$2.23M	Sell	19,900 -2,700	-12%	-$339K	0.06%	408
2021 Q2	$3.66M	Buy	22,600 +22,553	+47,985%	+$2.74M	0.12%	196
2021 Q1	$573K	Sell	47 -178	-79%	-$26.9K	0.02%	866
2020 Q4	$3.44M	Hold	225	–	–	0.13%	147
2020 Q3	$1.88M	Sell	225 -85	-27%	-$7.54K	0.11%	248
2020 Q2	$2.28M	Hold	310	–	–	0.16%	168
2020 Q1	$1.31M	Buy	310 +85	+38%	+$4.39K	0.11%	236
2019 Q4	$1.37M	Sell	225 -482	-68%	-$26.3K	0.12%	237
2019 Q3	$2.9M	Buy	707 +482	+214%	+$23K	0.27%	89
2019 Q2	$1.06M	Buy	+225	New	+$8.99K	0.1%	254

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boothbay Fund Management's CRSP Position: Q1 2024 in Review

Boothbay Fund Management sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 18,269 shares — an estimated $1.14M sold.

Boothbay Fund Management first reported a position in CRSP in Q2 2019 and held it in 6 quarters. The position peaked at $2.21M in Q2 2021. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

Boothbay Fund Management reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
Boothbay Fund Management sold 18,269 CRISPR Therapeutics shares in Q1 2024, an estimated $1.14M.
Boothbay Fund Management first reported a position in CRISPR Therapeutics in Q2 2019 and held it in 6 quarters.
Boothbay Fund Management's CRISPR Therapeutics position peaked at $2.21M in Q2 2021.
484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.